Select publications

Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46-53. Abstract

Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract

Gennari R et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10(17):5650-5. Abstract

Griggs JJ et al. Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer. Proc ASCO 2005;Abstract 793.

Jahanzeb M et al. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Proc ASCO 2005;Abstract 591.

Kostler WJ et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 2004;24(2C):1127-30. Abstract

Mehta RS et al. Phase II study of neoadjuvant biweekly doxorubicin and cyclophosphamide (AC) with GM-CSF followed by weekly paclitaxel, carboplatin +/- trastuzumab (TC +/- H) in the treatment of breast cancer (BC). Proc ASCO 2005;Abstract 826.

Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005;6(1):77-80. Abstract

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Ries LM et al. Neoadjuvant q4week carboplatin and weekly paclitaxel + trastuzumab in resectable and locally advanced breast cancer: A Brown University Oncology Group (BrUOG) study. Proc ASCO 2005;Abstract 759.

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Rueckert S et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: Trastuzumab. Expert Opin Biol Ther 2005;5(6):853-66. Abstract

Van Pelt AE et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 2003;4(5):348-53. Abstract

Wenzel C et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: A pilot study. J Cancer Res Clin Oncol 2004;130(7):400-4. Abstract

Select publications

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;[Epub ahead of print]. Abstract

Hess D et al; Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: A phase I trial (SAKK 25/99). Ann Oncol 2004;15(12):1760-5. Abstract

Leonard R et al. Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005. No abstract available

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Pierga JY et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004;88(2):117-29. Abstract

Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005;27(1):23-44. Abstract

Select publications

Aebi S et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355(9218):1869-74. Abstract

Baum M et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Castiglione-Gertsch M et al; International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95(24):1833-46. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996;348(9036):1189-96. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351(9114):1451-67. Abstract

Goldhirsch A et al. Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr 2001;30:44-51. Abstract

Goldhirsch A et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21(17):3357-65. Abstract

Harvey JM et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474-81. Abstract